Bio-Rad Laboratories, Inc.

Fundamentals6.0
Price Action4.0
News Sentiment5.0
AI Rating
4.0

Key Drivers

  • Strong Liquidity
  • Positive Cash Flow
  • Profitability Slump

AI
AI Summary

4.0

Bio-Rad should now be treated less as a pure quality-franchise story and more as a cash-rich turnaround bet, because strong liquidity and positive free cash flow cushion the downside but the recent quarterly loss means investors need proof that operating leverage and earnings can recover before the stock can sustainably reclaim the 300 level.

EarningsRisk
Turnaround‍
FreeCashFlow‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong Liquidity
  • Positive Cash Flow
  • Profitability Slump

BIO remains financially resilient with strong liquidity and positive free cash flow, but a steep quarterly net loss and negative EBIT/EBITDA have sharply weakened near-term earnings support.

liquidity
earnings

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Failed Breakout
  • Support Rebound
  • Lower Closes

Over the last month, BIO has been choppy and slightly weaker, rebounding sharply off the $270 area but still failing to break and hold above $300–$307, leaving the short-term setup mildly negative.

WeakTrend
RangeBound
Support Level: $280.00, then $270.32
Resistance Level: $300.00–$307.47

Sharp rebound from $270.32 to about $300.79, showing buyers stepped in after selloffs

Sentiment & News

5.0

Key News Insights:

  • Dealmaking Momentum
  • Activist Catalyst
  • Asset Monetization

BIO 2026 highlighted biotech partnering, AI, and global expansion, while Bio-Rad stood out on activist-driven value unlocking, potential Sartorius stake monetization, and tighter capital allocation.

biotech
BioRad

The news is modestly positive for Bio-Rad, as strategic pressure and asset actions could unlock value while sector-wide BIO 2026 attention supports visibility